期刊文献+

A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes 被引量:6

A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes
下载PDF
导出
摘要 AIM:To investigate the effectiveness of antioxidant compounds in modulating mitochondrial oxidative alterations and lipids accumulation in fatty hepatocytes.METHODS:Silybin-phospholipid complex containing vitamin E(Realsil) was daily administered by gavage(one pouch diluted in 3 mL of water and containing 15 mg vitamin E and 47 mg silybin complexed with phospholipids) to rats fed a choline-deprived(CD) or a high fat diet [20% fat,containing 71% total calories as fat,11% as carbohydrate,and 18% as protein,high fat diet(HFD)] for 30 d and 60 d,respectively.The control group was fed a normal semi-purified diet containing adequate levels of choline(35% total calories as fat,47% as carbohydrate,and 18% as protein).Circulating and hepatic redox active and nitrogen regulating molecules(thioredoxin,glutathione,glutathione peroxidase),NO metabolites(nitrosothiols,nitrotyrosine),lipid peroxides [malondialdehyde-thiobarbituric(MDA-TBA)],and pro-inflammatory keratins(K-18) were measured on days 0,7,14,30,and 60.Mitochondrial respiratory chain proteins and the extent of hepatic fatty infiltration were evaluated.RESULTS:Both diet regimens produced liver steatosis(50% and 25% of liver slices with CD and HFD,respectively) with no signs of necro-inflammation:fat infiltration ranged from large droplets at day 14 to disseminated and confluent vacuoles resulting in microvesicular steatosis at day 30(CD) and day 60(HFD).In plasma,thioredoxin and nitrosothiols were not significantly changed,while MDA-TBA,nitrotyrosine(from 6 ± 1 nmol/L to 14 ± 3 nmol/L day 30 CD,P < 0.001,and 12 ± 2 nmol/L day 60 HFD,P < 0.001),and K-18(from 198 ± 20 to 289 ± 21 U/L day 30 CD,P < 0.001,and 242 ± 23 U/L day 60 HFD,P < 0.001) levels increased significantly with ongoing steatosis.In the liver,glutathione was decreased(from 34.0 ± 1.3 to 25.3 ± 1.2 nmol/mg prot day 30 CD,P < 0.001,and 22.4 ± 2.4 nmol/mg prot day 60 HFD,P < 0.001),while thioredoxin and glutathione peroxidase were initially increased and then decreased.Nitrosothiols were constantly increased.MDA-TBA levels were five-fold increased from 9.1 ± 1.2 nmol/g to 75.6 ± 5.4 nmol/g on day 30,P < 0.001(CD) and doubled with HFD on day 60.Realsil administration significantly lowered the extent of fat infiltration,maintained liver glutathione levels during the first half period,and halved its decrease during the second half.Also,Realsil modulated thioredoxin changes and the production of NO derivatives and significantly lowered MDA-TBA levels both in liver(from 73.6 ± 5.4 to 57.2 ± 6.3 nmol/g day 30 CD,P < 0.01 and from 27.3 ± 2.1 nmol/g to 20.5 ± 2.2 nmol/g day 60 HFD,P < 0.01) and in plasma.Changes in mitochondrial respiratory complexes were also attenuated by Realsil in HFD rats with a major protective effect on Complex Ⅱ subunit CII-30.CONCLUSION:Realsil administration effectively contrasts hepatocyte fat deposition,NO derivatives formation,and mitochondrial alterations,allowing the liver to maintain a better glutathione and thioredoxin antioxidant activity. AIM: To investigate the effectiveness of antioxidant compounds in modulating mitochondrial oxidative alterations and lipids accumulation in fatty hepatocytes. METHODS: Silybin-phospholipid complex containing vitamin E (Realsil?) was daily administered by gavage (one pouch diluted in 3 mL of water and containing 15 mg vitamin E and 47 mg silybin complexed with phospholipids) to rats fed a choline-deprived (CD) or a high fat diet [20% fat, containing 71% total calories as fat, 11% as carbohydrate, and 18% as protein, high fat diet (HFD)] for 30 d and 60 d, respectively. The control group was fed a normal semi-purified diet containing adequate levels of choline (35% total calories as fat, 47% as carbohydrate, and 18% as protein). Circulating and hepatic redox active and nitrogen regulating molecules (thioredoxin, glutathione, glutathione peroxidase), NO metabolites (nitrosothiols, nitrotyrosine), lipid peroxides [malondialdehyde-thiobarbituric (MDA-TBA)], and pro-inflammatory keratins (K-18) were measured on days 0, 7, 14, 30, and 60. Mitochondrial respiratory chain proteins and the extent of hepatic fatty infiltration were evaluated. RESULTS: Both diet regimens produced liver steatosis (50% and 25% of liver slices with CD and HFD, respectively) with no signs of necro-inflammation: fat infiltration ranged from large droplets at day 14 to disseminated and confluent vacuoles resulting in microvesicular steatosis at day 30 (CD) and day 60 (HFD). In plasma, thioredoxin and nitrosothiols were not significantly changed, while MDA-TBA, nitrotyrosine (from 6 ± 1 nmol/L to 14 ± 3 nmol/L day 30 CD, P < 0.001, and 12 ± 2 nmol/L day 60 HFD, P < 0.001), and K-18 (from 198 ± 20 to 289 ± 21 U/L day 30 CD, P < 0.001, and 242 ± 23 U/L day 60 HFD, P < 0.001) levels increased significantly with ongoing steatosis. In the liver, glutathione was decreased (from 34.0 ± 1.3 to 25.3 ± 1.2 nmol/mg prot day 30 CD, P < 0.001, and 22.4 ± 2.4 nmol/mg prot day 60 HFD, P < 0.001), while thioredoxin and glutathione peroxidase were initially increased and then decreased. Nitrosothiols were constantly increased. MDA-TBA levels were five-fold increased from 9.1 ± 1.2 nmol/g to 75.6 ± 5.4 nmol/g on day 30, P < 0.001 (CD) and doubled with HFD on day 60. Realsil administration significantly lowered the extent of fat infiltration, maintained liver glutathione levels during the first half period, and halved its decrease during the second half. Also, Realsil modulated thioredoxin changes and the production of NO derivatives and significantly lowered MDA-TBA levels both in liver (from 73.6 ± 5.4 to 57.2 ± 6.3 nmol/g day 30 CD, P < 0.01 and from 27.3 ± 2.1 nmol/g to 20.5 ± 2.2 nmol/g day 60 HFD, P < 0.01) and in plasma. Changes in mitochondrial respiratory complexes were also attenuated by Realsil in HFD rats with a major protective effect on Complex II subunit CII-30. CONCLUSION: Realsil administration effectively contrasts hepatocyte fat deposition, NO derivatives formation, and mitochondrial alterations, allowing the liver to maintain a better glutathione and thioredoxin antioxidant activity.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第20期3007-3017,共11页 世界胃肠病学杂志(英文版)
基金 Supported by Grants from MIUR(Ministero Università e Ricerca Scientifica COFIN2006) "Fondi Ateneo Ricerca Scientifica 2005/2006" from the University of Bari,Italy
关键词 Fatty liver Glutathione Lipid PEROXIDATION NITROSOTHIOLS NITROTYROSINE THIOREDOXIN Fatty liver Glutathione Lipid peroxidation Nitrosothiols Nitrotyrosine Thioredoxin
  • 相关文献

参考文献13

  • 1Yusuf Yilmaz,Enver Dolar,Engin Ulukaya,Semra Akgoz,Murat Keskin,Murat Kiyici,Sibel Aker,Arzu Yilmaztepe,Selim Gurel,Macit Gulten,Selim Giray Nak.Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis[J].World Journal of Gastroenterology,2007,13(6):837-844. 被引量:19
  • 2Ariel R. Cardoso,Jo?o Victor Cabral-Costa,Alicia J. Kowaltowski.Effects of a high fat diet on liver mitochondria: increased ATP-sensitive K+ channel activity and reactive oxygen species generation[J].Journal of Bioenergetics and Biomembranes.2010(3)
  • 3Antonello Pietrangelo,Giuliana Montosi,Cinzia Garuti,Miranda Contri,Fabiola Giovannini,Daniela Ceccarelli,Alberto Masini.Iron-Induced Oxidant Stress in Nonparenchymal Liver Cells: Mitochondrial Derangement and Fibrosis in Acutely Iron-Dosed Gerbils and Its Prevention by Silybin[J].Journal of Bioenergetics and Biomembranes.2002(1)
  • 4Sanyal AJ,Campbell-sargent C,Mirshahi F,et al.Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities[].Gastroenterology.2001
  • 5Tietze,F.Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues[].Analytical Biochemistry.1969
  • 6Flohe L,Gunzler WA.Assays of glutathione peroxidase[].Methods in Enzymology.1984
  • 7Yu S,Matsusue K,Kashireddy P,et al.Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression[].Journal of Biological Chemistry.2003
  • 8Ferranti R,da Silva MM,Kowaltowski AJ.Mitochondrial ATP-sensitive K+ channel opening decreases reactive oxygen species generation[].FEBS Letters.2003
  • 9Nakamura H,Nakamura K,Yodoi J,et al.Redox regulation of cellular activation[].Annual Review of Immunology.1997
  • 10Morazzoni P,Montalbetti A,Malandrino S,et al.Comparative pharmacokinetics of silipide and silymarin in rats[].European Journal of Drug Metabolism and Pharmacokinetics.1993

二级参考文献36

  • 1[1]Brunt EM.Nonalcoholic steatohepatitis.Semin Liver Dis 2004; 24:3-20
  • 2[2]Sheth SG,Gordon FD,Chopra S.Nonalcoholic steatohepatitis.Ann Intern Med 1997; 126:137-145
  • 3[3]Bugianesi E,Leone N,Vanni E,Marchesini G,Brunello F,Carucci P,Musso A,De Paolis P,Capussotti L,Salizzoni M,Rizzetto M.Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma.Gastroenterology 2002; 123:134-140
  • 4[4]Marrero JA,Fontana RJ,Su GL,Conjeevaram HS,Emick DM,Lok AS.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 2002; 36:1349-1354
  • 5[5]Angulo P.Nonalcoholic fatty liver disease.N Engl J Med 2002; 346:1221-1231
  • 6[6]Van Ness MM,Diehl AM.Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473-478
  • 7[7]Sorbi D,Boynton J,Lindor KD.The ratio of aspartate aminotransferase to alanine aminotransferase:potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.Am J Gastroenterol 1999; 94:1018-1022
  • 8[8]McGill DB,Rakela T,Zinsmeister AR,Ott BJ.A 21-year experience with major hemorrhage after percutaneous liver biopsy.Gastroenterology 1990; 99:1396-1400
  • 9[9]Poynard T,Ratziu V,Bedossa P.Appropriateness of liver biopsy.Can J Gastroenterol 2000; 14:543-548
  • 10[10]Ratziu V,Charlotte F,Heurtier A,Gombert S,Giral P,Bruckert E,Grimaldi A,Capron F,Poynard T.Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology 2005; 128:1898-1906

共引文献18

同被引文献84

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部